Temozolomide in uterine leiomyosarcomas
- 1 July 2005
- journal article
- case report
- Published by Elsevier in Gynecologic Oncology
- Vol. 98 (1) , 99-103
- https://doi.org/10.1016/j.ygyno.2005.03.018
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989–1999Gynecologic Oncology, 2004
- Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyGynecologic Oncology, 2004
- Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterusGynecologic Oncology, 2003
- Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II TrialJournal of Clinical Oncology, 2002
- Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding TrialJournal of Clinical Oncology, 2002
- Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasEuropean Journal Of Cancer, 2002
- Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 1999
- Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group studyAmerican Journal of Obstetrics and Gynecology, 1992
- High-dose DTIC in advanced soft-tissue sarcomas in the adultAnnals of Oncology, 1991
- Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicinVersus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group)Cancer, 1985